Article title: Loss of KMT2D induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3
Author: Shidong Lv, Haoran Wen, Xiongwei Shan, Jianhua Li, Yaobin Wu, Xinpei Yu, Wenhua Huang and Qiang Wei
Journal: Epigenetics
Bibliometrics: Volume 14, Number 12, pages 1194-1208
DOI: 10.1080/15592294.2019.1634985.
The authors wish to make following correction to the article listed above.
In the , the flow cytometry profile of DU145 cells is incorrect due to a mistake in sample selecting. In the , the DAPI image on PC-3 shControl group was inadvertently duplicated during figure assembly. In the , the legends are mislabeled. The corrected are enclosed.
On page 14, “Cell chemotherapy response assay” section, the first two sentences should be “PC-3 cells (8 × 103) were seeded into 96-well plates. After incubation with common the genotoxic anticancer drugs doxorubicin and carboplatin or with PARP inhibitor olaparib for 72 h, cell viability was determined by quantifying the reduction of the tetrazolium dye MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to its insoluble formazan using standard MTT assays.”
The errors have no impact on the interpretation of the results, nor does it influence the conclusions of the work. Author apologize for any inconvenience that may have been caused.